P 11
Alternative Names: d-P11; P11; Ultra long acting GLP-1 analogue - ProtheragenLatest Information Update: 28 Jul 2024
At a glance
- Originator Protheragen
- Class Antihyperglycaemics; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (SC)
- 22 Jun 2020 Pharmacodynamics data from preclinical trials in Type 2 diabetes mellitus released by Protheragen, prior to June 2020 (Protheragen pipeline, June 2020)
- 22 Jun 2020 P 11 is available for licensing as of 22 Jun 2020. https://www.protheragen.com/pipeline/ultra-long-acting-glp-1-analogue/